Cytophage Technologies Ltd.
CYTO.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 652.50K | 608.50K | 723.50K | 676.70K | 801.30K |
| Depreciation & Amortization | 130.20K | 177.50K | 127.40K | 130.20K | 126.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 808.40K | 802.40K | 851.80K | 808.20K | 929.60K |
| Operating Income | -808.40K | -802.40K | -851.80K | -808.20K | -929.60K |
| Income Before Tax | -816.50K | -808.40K | -887.60K | -798.70K | -911.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -816.50K | -808.40K | -887.60K | -798.70K | -911.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -816.50K | -808.40K | -887.60K | -798.70K | -911.20K |
| EBIT | -808.40K | -802.40K | -851.80K | -808.20K | -929.60K |
| EBITDA | -725.00K | -669.90K | -770.60K | -725.50K | -803.00K |
| EPS Basic | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 55.66M | 53.94M | 53.94M | 53.83M | 53.76M |
| Average Diluted Shares Outstanding | 55.66M | 53.94M | 53.94M | 53.83M | 53.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |